Antiviral indolinyl compounds and uses thereof
JP2025517423A5Pending Publication Date: 2026-05-25GILEAD SCIENCES INC
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- GILEAD SCIENCES INC
- Filing Date
- 2023-05-18
- Publication Date
- 2026-05-25
AI Technical Summary
Technical Problem
Current treatments for herpes virus infections, such as those caused by HSV-1 and HSV-2, are limited by their inability to completely eliminate viral shedding, leading to ongoing transmission risks and inconvenient administration regimens.
Method used
Development of indolinyl compounds that inhibit the viral helicase-primase, potentially offering improved selectivity, potency, metabolic stability, and reduced adverse effects compared to existing nucleoside analogues.
Benefits of technology
The indolinyl compounds effectively inhibit herpes virus helicase-primase, potentially reducing viral replication and transmission, while providing a more favorable pharmacokinetic profile than current treatments.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2023225162000001 
Figure 2023225162000002 
Figure 2023225162000003
Abstract
The present disclosure relates to indolinyl compounds. The present disclosure further relates to compounds that inhibit viral helicase-primase. The present disclosure further relates to the use of the compounds for preparing medicaments for the treatment of diseases and / or conditions by inhibiting viral helicase-primase. The present disclosure also relates to the use of these compounds in the treatment of viral infections. The present disclosure further relates to intermediates for the preparation, and pharmaceutical compositions containing the compounds.
Need to check novelty before this filing date? Find Prior Art